Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Phase 2WithdrawnNCT04200989

Scripps Health

Overview

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.

Eligible subject undergo a baseline blinded oral peanut challenge. Then the peanut ILIT as described above. Pretreatment with antihistamines, leukotriene modifier and albuterol before each treatment. Following the three ILIT peanut injections a repeat blinded oral peanut challenge is performed. Blood is drawn at each of the 5 study visits for a variety of tests trying to elucidate the mechanism(s) of the induction of tolerance to peanut.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Food Allergy Peanut

Interventions

Peanut allergenBIOLOGICAL

Intralymphatic immunotherapy injections.

Eligibility

Sex: ALLMin age: 15 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: History of peanut allergy Positive prick skin tests or invitro IgE to peanut Positive blinded oral peanut challenge. \- Exclusion Criteria: History of * life threatening anaphylaxis to peanut Uncontrolled asthma

Locations (1)

Scripps Clinic

San Diego, California, United States

Outcomes

Primary Outcomes

Peanut tolerance

Increase in amount (mg - grams) of peanut ingested without reaction from baseline to one month post ILIT

Time frame: 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.